Press Releases

Feb 21, 2024
LONDON --(BUSINESS WIRE)--Feb. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights 1 Fourth-quarter revenue of $310.1 million
Feb 05, 2024
William Kozy will remain Board Chair LONDON --(BUSINESS WIRE)--Feb. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of
Jan 08, 2024
Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LONDON --(BUSINESS WIRE)--Jan. 8, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today
Jan 04, 2024
LONDON --(BUSINESS WIRE)--Jan. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).